Ida Vanessa Döederlein Schwartz

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · The Journal of Pediatrics · 2006 · 364 citations

Life Sciences, Biochemistry, Pharmacotherapy +7

Gender, Race and Parenthood Impact Academic Productivity During the COVID-19 Pandemic: From Survey to Action

Fernanda Stanisçuaski, Lívia Kmetzsch, Rossana C. Soletti et al. · Frontiers in Psychology · 2021 · 274 citations · Full text

Education, Gender Studies, Higher Education +17

Impact of COVID-19 on academic mothers

Fernanda Stanisçuaski, Fernanda Maciel Reichert, Fernanda P. Werneck et al. · Science · 2020 · 220 citations

Social Sciences, Gender Studies, Science Education +9

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 216 citations

Life Sciences, Biochemistry, Clinical Biochemistry +8

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Stuart J. Swiedler, Michael Beck, M Bajbouj et al. · American Journal of Medical Genetics Part A · 2005 · 162 citations

Medicine, Neurology, Molecular Pathology +12